146 related articles for article (PubMed ID: 35531363)
1. Response to anti-DKK1 therapy in uterine carcinosarcoma: A case report.
ElNaggar A; Zhang N; Scalise CB; Sirard C; Kagey MH; Vaena D; Arend R
Gynecol Oncol Rep; 2022 Feb; 39():100904. PubMed ID: 35531363
[TBL] [Abstract][Full Text] [Related]
2. DKK1 is a predictive biomarker for response to DKN-01: Results of a phase 2 basket study in women with recurrent endometrial carcinoma.
Arend R; Dholakia J; Castro C; Matulonis U; Hamilton E; Jackson CG; LyBarger K; Goodman HM; Duska LR; Mahdi H; ElNaggar AC; Kagey MH; Liu A; Piper D; Barroilhet LM; Bradley W; Sachdev J; Sirard CA; O'Malley DM; Birrer M
Gynecol Oncol; 2023 May; 172():82-91. PubMed ID: 37001446
[TBL] [Abstract][Full Text] [Related]
3. The anti-DKK1 antibody DKN-01 as an immunomodulatory combination partner for the treatment of cancer.
Wall JA; Klempner SJ; Arend RC
Expert Opin Investig Drugs; 2020 Jul; 29(7):639-644. PubMed ID: 32408777
[TBL] [Abstract][Full Text] [Related]
4. Tumor Mutational Burden Guides Therapy in a Treatment Refractory
Bhangoo MS; Boasberg P; Mehta P; Elvin JA; Ali SM; Wu W; Klempner SJ
Oncologist; 2018 May; 23(5):518-523. PubMed ID: 29386312
[TBL] [Abstract][Full Text] [Related]
5. Wnt signaling modulator DKK1 as an immunotherapeutic target in ovarian cancer.
Betella I; Turbitt WJ; Szul T; Wu B; Martinez A; Katre A; Wall JA; Norian L; Birrer MJ; Arend R
Gynecol Oncol; 2020 Jun; 157(3):765-774. PubMed ID: 32192732
[TBL] [Abstract][Full Text] [Related]
6. Phase I and Biomarker Study of the Wnt Pathway Modulator DKN-01 in Combination with Gemcitabine/Cisplatin in Advanced Biliary Tract Cancer.
Goyal L; Sirard C; Schrag M; Kagey MH; Eads JR; Stein S; El-Khoueiry AB; Manji GA; Abrams TA; Khorana AA; Miksad R; Mahalingam D; Zhu AX; Duda DG
Clin Cancer Res; 2020 Dec; 26(23):6158-6167. PubMed ID: 32878766
[TBL] [Abstract][Full Text] [Related]
7. Durable complete remission with aromatase inhibitor therapy in a patient with metastatic uterine carcinosarcoma with poor performance status and coagulation disorders: a case report.
Martin-Romano P; Jurado M; Idoate MA; Arbea L; Hernandez-Lizoain JL; Cano D; Paramo JA; Martin-Algarra S
J Med Case Rep; 2017 Apr; 11(1):115. PubMed ID: 28424084
[TBL] [Abstract][Full Text] [Related]
8. Safety, Efficacy, and Biomarker Results from a Phase Ib Study of the Anti-DKK1 Antibody DKN-01 in Combination with Pembrolizumab in Advanced Esophagogastric Cancers.
Klempner SJ; Bendell JC; Villaflor VM; Tenner LL; Stein SM; Rottman JB; Naik GS; Sirard CA; Kagey MH; Chaney MF; Strickler JH
Mol Cancer Ther; 2021 Nov; 20(11):2240-2249. PubMed ID: 34482288
[TBL] [Abstract][Full Text] [Related]
9. HDAC Inhibition Induces Cell Cycle Arrest and Mesenchymal-Epithelial Transition in a Novel Pleural-Effusion Derived Uterine Carcinosarcoma Cell Line.
Stockhammer P; Okumus Ö; Hegedus L; Rittler D; Ploenes T; Herold T; Kalbourtzis S; Bankfalvi A; Sucker A; Kimmig R; Aigner C; Hegedus B
Pathol Oncol Res; 2021; 27():636088. PubMed ID: 34257602
[No Abstract] [Full Text] [Related]
10. Adjuvant radiotherapy and/or chemotherapy after surgery for uterine carcinosarcoma.
Galaal K; van der Heijden E; Godfrey K; Naik R; Kucukmetin A; Bryant A; Das N; Lopes AD
Cochrane Database Syst Rev; 2013 Feb; 2013(2):CD006812. PubMed ID: 23450572
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant radiotherapy and/or chemotherapy after surgery for uterine carcinosarcoma.
Galaal K; Godfrey K; Naik R; Kucukmetin A; Bryant A
Cochrane Database Syst Rev; 2011 Jan; (1):CD006812. PubMed ID: 21249682
[TBL] [Abstract][Full Text] [Related]
12. Exceptional Response of Cryoablation Followed by Pembrolizumab in a Patient with Metastatic Cervical Carcinosarcoma with High Tumor Mutational Burden: A Case Report.
Zhu B; Liu Y; Li J; Diao L; Shao L; Han-Zhang H; Zhang L; Kang Q; Yang W
Oncologist; 2020 Jan; 25(1):15-18. PubMed ID: 31848313
[TBL] [Abstract][Full Text] [Related]
13. [Ifosfamide and Paclitaxel for Recurrent or Metastatic Uterine Carcinosarcoma].
Ohtake Y; Sudo K; Kojima Y; Seo T; Okuma H; Nishikawa T; Uno M; Uehara T; Ishikawa M; Tanioka M; Noguchi E; Shimomura A; Yonemori K; Kato T; Fujiwara Y; Tamura K
Gan To Kagaku Ryoho; 2019 Oct; 46(10):1525-1529. PubMed ID: 31631133
[TBL] [Abstract][Full Text] [Related]
14. A phase II trial of paclitaxel and carboplatin in women with advanced or recurrent uterine carcinosarcoma.
Lacour RA; Euscher E; Atkinson EN; Sun CC; Ramirez PT; Coleman RL; Brown J; Gano JB; Burke TW; Ramondetta LM
Int J Gynecol Cancer; 2011 Apr; 21(3):517-22. PubMed ID: 21436700
[TBL] [Abstract][Full Text] [Related]
15. Crosstalk between PI3K/AKT/mTOR and WNT/β-Catenin signaling in GBM - Could combination therapy checkmate the collusion?
Daisy Precilla S; Biswas I; Kuduvalli SS; Anitha TS
Cell Signal; 2022 Jul; 95():110350. PubMed ID: 35525406
[TBL] [Abstract][Full Text] [Related]
16. Uterine carcinosarcoma: Contemporary clinical summary, molecular updates, and future research opportunity.
Matsuzaki S; Klar M; Matsuzaki S; Roman LD; Sood AK; Matsuo K
Gynecol Oncol; 2021 Feb; 160(2):586-601. PubMed ID: 33183764
[TBL] [Abstract][Full Text] [Related]
17. mDKN-01, a Novel Anti-DKK1 mAb, Enhances Innate Immune Responses in the Tumor Microenvironment.
Haas MS; Kagey MH; Heath H; Schuerpf F; Rottman JB; Newman W
Mol Cancer Res; 2021 Apr; 19(4):717-725. PubMed ID: 33443105
[TBL] [Abstract][Full Text] [Related]
18. Clinical experience with combination paclitaxel and carboplatin therapy for advanced or recurrent carcinosarcoma of the uterus.
Toyoshima M; Akahira J; Matsunaga G; Niikura H; Ito K; Yaegashi N; Tase T
Gynecol Oncol; 2004 Sep; 94(3):774-8. PubMed ID: 15350372
[TBL] [Abstract][Full Text] [Related]
19. Discordances in expression of human epidermal growth factor receptor 2 between primary and metastatic uterine carcinosarcoma: A proposal for HER2-targeted therapy specimen selection.
Yoshida H; Mizoguchi C; Saito A; Kitadai R; Yamamoto K; Nishikawa T; Kato T; Yonemori K
Ann Diagn Pathol; 2023 Aug; 65():152150. PubMed ID: 37119646
[TBL] [Abstract][Full Text] [Related]
20. Crosstalk of estrogen receptors and Wnt/β-catenin signaling in endometrial cancer.
Kasoha M; Dernektsi C; Seibold A; Bohle RM; Takacs Z; Ioan-Iulian I; Solomayer EF; Juhasz-Böss I
J Cancer Res Clin Oncol; 2020 Feb; 146(2):315-327. PubMed ID: 31865530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]